TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.

doi:10.1016/j.jtct.2023.03.008

Article

TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Transplantation and cellular therapy - 1 Jun 2023

Marvin-Peek Jennifer, Mason Emily F, Kishtagari Ashwin, Jayani Reena V, Dholaria Bhagirathbhai, Kim Tae Kon, Engelhardt Brian G, Chen Heidi, Strickland Stephen, Savani Bipin, Ferrell Brent, Kassim Adetola, Savona Michael, Mohan Sanjay, Byrne Michael

Abstract excerpt

Although allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy for patients with poor-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), only a minority of these patients undergo HCT. Patients with TP53-mutated (TP53MUT) MDS/AML are at particularly high risk, yet fewer TP53MUT patients undergo HCT compared with poor-risk TP53-wild type (TP53WT) patients....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hematopoietic Stem Cell Transplantation

TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Abstract excerpt

Topics

Related research